Summary
Carboplatin, a new platinum analogue, was administered intravenously on a schedule of a single dose every five weeks to 23 patients with advanced malignant solid tumors. Patients were treated at six dosage levels ranging from 200–550 mg/m2 every five weeks. Thrombocytopenia was dose-limiting. At 550 mg/m2 Carboplatin, the median platelet nadir was 65 000/mm3. Leukopenia was common, but usually of mild to moderate degree. Gastrointestinal upset was commonly seen at all dose levels, but 35% of the patients experienced no vomiting. No significant increase of the serum creatinine following Carboplatin was seen. In 16 patients serial determinations of the creatinine clearance were performed. The median base line creatinine clearance was 87 (50–155) ml/min and dropped to a median lowest creatinine clearance of 69 (23–171) ml/min on day four (p < 0.05). The median creatinine clearance before the next Carboplatin treatment was 89 (42–155) ml/min. No significant proteinuria or electrolyte disturbances were noted. Carboplatin exhibited antitumor activity in ovarian, endometrial, thyroid and gastric carcinomas. The maximally tolerated dose appears to be 550 mg/m2 every five weeks. A starting dose of 450 mg/m2 seems to be appropriate for Phase II studies. In patients with impaired renal function and/or prior cis-Platin chemotherapy, Carboplatin at doses of 200–500
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Prestayko AW, D'Aoust JC, Issell BF, Crooke ST: Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 6:17–39, 1979
Cavalli F, Jungi WF, Sonntag RW, Nissen NI, Holland JF: Phase II trial of cis-Dichlorodiammine-platinum (II) in advanced malignant lymphoma and small cell lung cancer: preliminary results. Cancer Treat Rep 63:1599–1603, 1979
De Jager R, Longeval E, Klastersky J: High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC lung cancer working party (Belgium). Cancer Treat Rep 64:1341–1346, 1980
Krakoff IH: Nephrotoxicity of cis-Dichlorodiammine-platinum(II). Cancer Treat Rep 63:1523–1525, 1979
Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM: Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63:1527–1531, 1979
Carter SK: Design of clinical trials with cisplatin analogues. In: Prestayko AW, Crooke ST, Carter SK (eds): Cisplatin. Current Status and New Developments. Academic Press, New York 1980, pp 511–516.
Wilkinson R, Cox PJ, Jones M: Selection of potential second generation platinum compounds. Biochemie 60:851–857, 1978
Lee FH, Canetta R, Issell BF, Lenaz L: New platinum complexes in clinical trials. Cancer Treat Rev 10:39–51, 1983
Harrap KR, Jones M, Wilkinson CR: Antitumor, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Prestayko AW, Crooke ST, Carter SK (eds): Cisplatin — Current Status and New Developments. Academic Press, New York 1980, pp 1943–212
Rose WC, Schurig JE, Bradner WT, Huftalen JB: Antitumor activity and toxicity of cis-diamminedichloroplatinum(II) analogs. Cancer Treat Rep 66:135–146, 1982
Harland SJ, Calvert AH, Siddik ZH, Newell Dr, Wilshaw E, Jones A, Baker JW, Smith IE, McElwain TJ, Harrap KR: Phase I study of cis-diammine-1,1-cyclobutane dicarbocylate platinum II (CBDCA). Abstract 50, Third NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, October 1981
WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979
Bartosek I, Cattaneo MT: Electrochemical determination of submicrogram quantities of DDP in biological samples. In: Periti P, Gialdroni Grass G (eds): Current Chemotherapy and Immunotherapy. Vol. 12. American Society for Microbiology, Washington D.C., 1982, pp 1382–1383
Notary RE, DeYoung YL: Biopharmaceutics and Pharmocokinetics. Marcell Dekker, New York, 1985, pp 79–99
Harrap KR: Platinum analogues: Criteria for selection. In: Muggia FM (ed): Cancer Chemotherapy 1. Cancer Treatment and Research Vol. 7. Martinus Nijhoff Publishers, The Hague, Boston, London, 1983, pp 171–217
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Pechkam MJ, Harrap KR: Early clinical studies with cis-Diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147, 1982
Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM: A phase I and pharmacokinetic study of Diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Research 43:4470–4473, 1983
Rozencweig M, Nicaise C, Beer M, Crespeigne N, Van Rijmenant M, Lenaz L, Kenis Y: Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol 1:621–626, 1983
Beretta R, Cattaneo MT, Damiani E, Sessa C, Zucca E, Cavalli F: Enzymuria after cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) administration. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 1983, Part 274, pp 124–129
Wolpert-De Fillipes MK: Antitumor activity of cisplatin analogs. In: Prestayko AW, Crooke ST, Carter SK (eds): Cisplatin-Current Status and New Developments. Academic Press, New York, 1980, pp 183–191
Wiltshaw E, Evans BD, Jones AC, Baker JW, Calvert AH: JM8, successor to cisplatin in advanced ovarian carcinoma? The Lancet 1:587, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Joss, R.A., Kaplan, S., Goldhirsch, A. et al. A Phase I trial of Cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs 2, 297–304 (1984). https://doi.org/10.1007/BF00175380
Issue Date:
DOI: https://doi.org/10.1007/BF00175380